Goldman Sachs Group Inc. Has $998,000 Stock Position in Personalis, Inc. $PSNL

Goldman Sachs Group Inc. boosted its holdings in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 55.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 284,426 shares of the company's stock after buying an additional 101,706 shares during the period. Goldman Sachs Group Inc. owned approximately 0.32% of Personalis worth $998,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of PSNL. Aberdeen Group plc grew its stake in Personalis by 472.3% in the first quarter. Aberdeen Group plc now owns 1,704,784 shares of the company's stock valued at $5,984,000 after purchasing an additional 1,406,895 shares in the last quarter. ARK Investment Management LLC grew its stake in Personalis by 6.1% in the first quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company's stock valued at $25,231,000 after purchasing an additional 412,762 shares in the last quarter. AIGH Capital Management LLC grew its stake in Personalis by 4.5% in the first quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company's stock valued at $13,931,000 after purchasing an additional 169,884 shares in the last quarter. Trexquant Investment LP grew its stake in Personalis by 455.0% in the first quarter. Trexquant Investment LP now owns 122,959 shares of the company's stock valued at $432,000 after purchasing an additional 100,804 shares in the last quarter. Finally, Squarepoint Ops LLC grew its stake in Personalis by 438.7% in the fourth quarter. Squarepoint Ops LLC now owns 91,684 shares of the company's stock valued at $530,000 after purchasing an additional 74,664 shares in the last quarter. 61.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on PSNL shares. Wall Street Zen upgraded Personalis from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright reiterated a "buy" rating and set a $8.50 price target on shares of Personalis in a research note on Monday, September 8th. Finally, BTIG Research set a $6.00 price target on Personalis in a research note on Wednesday, August 6th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Personalis presently has a consensus rating of "Buy" and a consensus price target of $7.42.

Personalis Trading Up 1.0%

Shares of PSNL opened at $6.16 on Tuesday. Personalis, Inc. has a 1 year low of $2.83 and a 1 year high of $7.79. The stock has a 50 day simple moving average of $5.40 and a 200-day simple moving average of $4.94. The stock has a market cap of $546.27 million, a PE ratio of -4.81 and a beta of 1.76.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The business had revenue of $17.20 million during the quarter, compared to analysts' expectations of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts forecast that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.